肝细胞
毒性
诱导多能干细胞
生物人工肝装置
体内
药品
细胞
药物开发
肝毒性
药理学
药物代谢
肝细胞
细胞培养
体外毒理学
干细胞
优先次序
生物
体外
细胞生物学
医学
生物化学
胚胎干细胞
生物技术
内科学
管理科学
经济
基因
遗传学
作者
Maria-José Gómez-Lechón,Laia Tolosa,Isabel Conde,Maria Francesca Donato
标识
DOI:10.1517/17425255.2014.967680
摘要
The liver is the most important target for drug-induced toxicity. This vulnerability results from functional liver features and its role in the metabolic elimination of most drugs. Drug-induced liver injury is a significant leading cause of acute, chronic liver disease and an important safety issue when developing new drugs.This review describes the advantages and limitations of hepatic cell-based models for early safety risk assessment during drug development. These models include hepatocytes cultured as monolayer, collagen-sandwich; emerging complex 3D configuration; liver-derived cell lines; stem cell-derived hepatocytes.In vitro toxicity assays performed in hepatocytes or hepatoma cell lines can potentially provide rapid and cost-effective early feedback to identify toxic candidates for compound prioritization. However, their capacity to predict hepatotoxicity depends critically on cells' functional performance. In an attempt to improve and prolong functional properties of cultured cells, different strategies to recreate the in vivo hepatocyte environment have been explored. 3D cultures, co-cultures of hepatocytes with other cell types and microfluidic devices seem highly promising for toxicological studies. Moreover, hepatocytes derived from human pluripotent stem cells are emerging cell-based systems that may provide a stable source of hepatocytes to reliably screen metabolism and toxicity of candidate compounds.
科研通智能强力驱动
Strongly Powered by AbleSci AI